Arcutis Biotherapeutics/$ARQT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcutis Biotherapeutics
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Ticker
$ARQT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
342
ISIN
US03969K1088
Website
ARQT Metrics
BasicAdvanced
$1.6B
-
-$1.04
1.87
-
Price and volume
Market cap
$1.6B
Beta
1.87
52-week high
$17.75
52-week low
$6.99
Average daily volume
1.9M
Financial strength
Current ratio
3.552
Quick ratio
3.111
Long term debt to equity
77.078
Total debt to equity
77.668
Interest coverage (TTM)
-5.35%
Management effectiveness
Return on assets (TTM)
-18.43%
Return on equity (TTM)
-70.58%
Valuation
Price to revenue (TTM)
8.01
Price to book
11.42
Price to tangible book (TTM)
12.91
Price to free cash flow (TTM)
-14.609
Growth
Revenue change (TTM)
100.03%
Earnings per share change (TTM)
-60.88%
3-year earnings per share growth (CAGR)
-39.39%
What the Analysts think about ARQT
Analyst ratings (Buy, Hold, Sell) for Arcutis Biotherapeutics stock.
ARQT Financial Performance
Revenues and expenses
ARQT Earnings Performance
Company profitability
ARQT News
AllArticlesVideos
Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·22 hours ago
Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
GlobeNewsWire·1 week ago
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcutis Biotherapeutics stock?
Arcutis Biotherapeutics (ARQT) has a market cap of $1.6B as of May 30, 2025.
What is the P/E ratio for Arcutis Biotherapeutics stock?
The price to earnings (P/E) ratio for Arcutis Biotherapeutics (ARQT) stock is 0 as of May 30, 2025.
Does Arcutis Biotherapeutics stock pay dividends?
No, Arcutis Biotherapeutics (ARQT) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next Arcutis Biotherapeutics dividend payment date?
Arcutis Biotherapeutics (ARQT) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcutis Biotherapeutics?
Arcutis Biotherapeutics (ARQT) has a beta rating of 1.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.